Bright Minds Biosciences Inc.
DRUG
Kedudukan dalam Saham
#12649
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics... Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Harga Saham
$54.34
Modal Pasaran
$536.04M
Perubahan (1 hari)
-1.55%
Perubahan (1 tahun)
-19.37%
Negara
US
Perdagangan Bright Minds Biosciences Inc. (DRUG)
Kategori
Healthcare
Sejarah pecahan saham untuk Bright Minds Biosciences Inc. (DRUG)
Saham Bright Minds Biosciences Inc. (simbol: DRUG) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham DRUG yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham DRUG.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham DRUG yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham DRUG.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
